Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00046943 · ClinicalTrials.gov registry record · Phase 3
Atrasentan in Treating Patients With Prostate Cancer
A Phase 3 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00046943: Completed Phase 3 study, sponsored by Abbott.
NCT00046943 is a Phase 3 study that has completed, run by Abbott. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00046943, a Phase 3 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase III trial to determine the effectiveness of atrasentan in treating patients who have prostate cancer that has not responded to hormone therapy.
Interventions
- DRUG atrasentan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-09 |
| Phase | Phase 3 |
What the finished NCT00046943 record still lists
NCT00046943 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which atrasentan hydrochloride is the first listed.
NCT00046943 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00046943 about?
NCT00046943 is a clinical study titled "Atrasentan in Treating Patients With Prostate Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase III trial to determine the effectiveness of atrasentan in treating patients who have prostate cancer that has not responded to hormone therapy.
What is the current status of trial NCT00046943?
This trial is currently completed. It is a Phase 3 study. The study started on 2002-09.
What interventions are being tested in trial NCT00046943?
The interventions under investigation include: atrasentan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00046943?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia